Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01GJ7FYMJCFV23RRDKTV80WF0G> ?p ?o. }
Showing items 1 to 22 of
22
with 100 items per page.
- 01GJ7FYMJCFV23RRDKTV80WF0G classification A1.
- 01GJ7FYMJCFV23RRDKTV80WF0G date "2022".
- 01GJ7FYMJCFV23RRDKTV80WF0G language "eng".
- 01GJ7FYMJCFV23RRDKTV80WF0G type journalArticle.
- 01GJ7FYMJCFV23RRDKTV80WF0G hasPart 01GJ7G5KZ9CTJRW6A0G4009Y23.pdf.
- 01GJ7FYMJCFV23RRDKTV80WF0G subject "Medicine and Health Sciences".
- 01GJ7FYMJCFV23RRDKTV80WF0G doi "10.1007/s40266-022-00984-5".
- 01GJ7FYMJCFV23RRDKTV80WF0G issn "1170-229X".
- 01GJ7FYMJCFV23RRDKTV80WF0G issn "1179-1969".
- 01GJ7FYMJCFV23RRDKTV80WF0G volume "39".
- 01GJ7FYMJCFV23RRDKTV80WF0G abstract "Recently, major trials have explored blood pressure targets that would provide greater benefit and fewer adverse events in older adult population on antihypertensive treatment. The last study was the STEP study conducted in China, which included 8511 older people aged 60-80 years. When systolic blood pressure below 130 mmHg was targeted in older individuals, there was a 26% risk reduction in cardiovascular outcomes compared with higher (< 150 mmHg) blood pressure values. At this point, it is necessary to evaluate how much the study group represents the older population because this population group is very heterogeneous, and it is not possible to apply a single treatment strategy to all older people. In this context, when we examined the baseline characteristics of the study group, we saw that the individuals included in the study consisted mostly of young-older people with less accompanying comorbidities. In addition, vulnerable groups, such as those with dementia and nursing home residents who are susceptible to treatment adverse effects, appeared to be excluded from the study. Therefore, this trial is very important as it concludes that the goal of strict blood pressure control is beneficial in fit older individuals, but does not guide treatment strategy for other groups. When planning treatments in older adults, it is essential to consider the biological age of individuals and to determine a strategy by evaluating frailty, functionality and cognitive status. As stated in the STEP study protocol, additional analyses considering frailty and cognitive performance will aid in a healthier interpretation of the study in the future.".
- 01GJ7FYMJCFV23RRDKTV80WF0G author F7148516-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GJ7FYMJCFV23RRDKTV80WF0G author urn:uuid:24e570d4-6456-4b4b-a078-bbaef10918be.
- 01GJ7FYMJCFV23RRDKTV80WF0G author urn:uuid:937120d3-0f4e-4349-92a8-f759086b965c.
- 01GJ7FYMJCFV23RRDKTV80WF0G dateCreated "2022-11-19T08:26:48Z".
- 01GJ7FYMJCFV23RRDKTV80WF0G dateModified "2024-11-27T13:28:13Z".
- 01GJ7FYMJCFV23RRDKTV80WF0G name "Treating hypertension in older adults in light of the recent STEP trial : can we implement the findings in geriatric practice?".
- 01GJ7FYMJCFV23RRDKTV80WF0G pagination urn:uuid:3ccf2098-a7a1-4200-94e2-db2844cf3446.
- 01GJ7FYMJCFV23RRDKTV80WF0G publisher urn:uuid:bd63fd20-ec9f-46e1-946a-54958a9a2132.
- 01GJ7FYMJCFV23RRDKTV80WF0G sameAs LU-01GJ7FYMJCFV23RRDKTV80WF0G.
- 01GJ7FYMJCFV23RRDKTV80WF0G sourceOrganization urn:uuid:07d30454-3127-46c4-8838-e7711911bf4a.
- 01GJ7FYMJCFV23RRDKTV80WF0G type A1.